Hunting ALK to feed targeted cancer therapy
نویسندگان
چکیده
منابع مشابه
Targeted cancer therapy: review article
Cancer is one of the most dangerous health problems of today modern societies which has an increasing rate especially in developing countries. There are many diverse ongoing treatment attempts trying to defeat cancer. Despite that, scientists have been unable to find a permanent cure for this disease. In many cases although there is a successful first response in patients, cancer cells are fina...
متن کاملALK-targeted therapy for lung cancer: ready for prime time.
Lung cancer remains the leading cause of cancer-related death in the United States. Ongoing research into the molecular basis of lung cancer has yielded insight into various critical pathways that are deregulated in lung tumorigenesis, and in particular key driver mutations integral to cancer cell survival and proliferation. One of the most recent examples of this has been definition of translo...
متن کاملALK and NSCLC: Targeted therapy with ALK inhibitors
For many years treatment for advanced or metastatic non-small cell lung cancer (NSCLC) has employed chemotherapy regimens for patient care, with limited effect. Five-year survival rates for these patients are not encouraging. However, for a subgroup of these patients, there have been radical changes over recent years. Our understanding of the basic pathology behind NSCLC at the molecular level ...
متن کاملAdvances in ALK Targeted Therapy for Neuroblastoma
Significant advances have been made to understand the association between ALK genetic aberrations and disease prognosis in neuroblastoma. ALK targeted therapies are evolving quickly and several randomized controlled trials of ALK inhibitors are underway or nearing completion in adult cancers. Ongoing research will bring new challenges and newer technologies to fully define the pathogenic and pr...
متن کاملResistance to HER2-targeted therapy
Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment. However, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due to development of resistance to the drug. The majority of patients who benefit from the drug...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Medicine
سال: 2011
ISSN: 1078-8956,1546-170X
DOI: 10.1038/nm0311-290